WuXi XDC Cayman company profile
Company profile
WuXi XDC Cayman has 3,628 employees and is headquartered in Wuxi, China.
Operating in China, North America, Europe and other international markets, WuXi XDC Cayman Inc. provides contract research, development and manufacturing services. Its work covers the discovery, development and production of drug substances and drug products built on antibody-drug conjugates, bioconjugates and monoclonal antibody intermediates, along with payload-linker components. The company also develops and markets anti-tumor drugs and offers international sales contracting services. It has a strategic collaboration with Earendil Labs and with Akari Therapeutics.
The company was founded in 2013, is headquartered in Wuxi, China, and employs 3,628 people. In the fiscal year ended December 2025, revenue reached CNY 5.9 billion, a 46.7% increase, and net profit was CNY 1.5 billion. It is a subsidiary of WuXi Biologics (Cayman) Inc.
Company facts
- Sector
- Industrials
- Industry
- Diagnostics & Research
- Country
- Hong Kong SAR China
- Headquarters
- No. 11 Xinhui Ring Road, Wuxi
- Employees
- 3,628
- Chief executive
- Jincai Li
- Founded
- 2013
- Fiscal year
- January - December
- Listing
- 2268 · HKEX
- Currency
- HKD
- ISIN
- KYG9808A1058
- Website
- wuxixdc.com
WuXi XDC Cayman and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| WuXi XDC Cayman2268 | Hong Kong SAR China | $9.64B | 3,628 | 28.1% | 46.6 |
| Sonic HealthcareSHL | Australia | $7.13B | 47,000 | 9.3% | 17.6 |
| WuXi AppTec603259 | China | $63.99B | 33,834 | 44.8% | 15.7 |
| QiagenQIA | Germany | $10.23B | 5,400 | 26.7% | 28.5 |
| bioMérieuxBIM | France | $11.84B | 14,562 | 16.0% | 23.4 |
| ICON PublicICLR | United States | $13.99B | 40,250 | 2.7% | 74.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
